These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 25351579

  • 1. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
    Wen Q, Jalilian L, Lupo JM, Molinaro AM, Chang SM, Clarke J, Prados M, Nelson SJ.
    J Neurooncol; 2015 Jan; 121(2):331-9. PubMed ID: 25351579
    [Abstract] [Full Text] [Related]

  • 2. Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab.
    Nelson SJ, Li Y, Lupo JM, Olson M, Crane JC, Molinaro A, Roy R, Clarke J, Butowski N, Prados M, Cha S, Chang SM.
    J Neurooncol; 2016 Oct; 130(1):171-179. PubMed ID: 27535746
    [Abstract] [Full Text] [Related]

  • 3. Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
    Kim JH, Choi SH, Ryoo I, Yun TJ, Kim TM, Lee SH, Park CK, Kim JH, Sohn CH, Park SH, Kim IH.
    PLoS One; 2014 Oct; 9(11):e113587. PubMed ID: 25419975
    [Abstract] [Full Text] [Related]

  • 4. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.
    Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel PS, Lai A, Nghiemphu P, Rahmanuddin S, Goldin J.
    Radiology; 2009 Jul; 252(1):182-9. PubMed ID: 19561256
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen.
    Nelson SJ, Kadambi AK, Park I, Li Y, Crane J, Olson M, Molinaro A, Roy R, Butowski N, Cha S, Chang S.
    Neuro Oncol; 2017 Mar 01; 19(3):430-439. PubMed ID: 27576874
    [Abstract] [Full Text] [Related]

  • 8. Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.
    Zhang M, Gulotta B, Thomas A, Kaley T, Karimi S, Gavrilovic I, Woo KM, Zhang Z, Arevalo-Perez J, Holodny AI, Rosenblum M, Young RJ.
    Neuro Oncol; 2016 May 01; 18(5):735-43. PubMed ID: 26538618
    [Abstract] [Full Text] [Related]

  • 9. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.
    Narayana A, Gruber D, Kunnakkat S, Golfinos JG, Parker E, Raza S, Zagzag D, Eagan P, Gruber ML.
    J Neurosurg; 2012 Feb 01; 116(2):341-5. PubMed ID: 22035272
    [Abstract] [Full Text] [Related]

  • 10. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
    Hainsworth JD, Shih KC, Shepard GC, Tillinghast GW, Brinker BT, Spigel DR.
    Clin Adv Hematol Oncol; 2012 Apr 01; 10(4):240-6. PubMed ID: 22706484
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.
    Ellingson BM, Cloughesy TF, Lai A, Mischel PS, Nghiemphu PL, Lalezari S, Schmainda KM, Pope WB.
    Neuro Oncol; 2011 Oct 01; 13(10):1151-61. PubMed ID: 21856685
    [Abstract] [Full Text] [Related]

  • 14. Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients.
    Rulseh AM, Vymazal J.
    J Neurooncol; 2020 Jan 01; 146(1):157-162. PubMed ID: 31797235
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.
    Ney DE, Carlson JA, Damek DM, Gaspar LE, Kavanagh BD, Kleinschmidt-DeMasters BK, Waziri AE, Lillehei KO, Reddy K, Chen C.
    J Neurooncol; 2015 Mar 01; 122(1):135-43. PubMed ID: 25524817
    [Abstract] [Full Text] [Related]

  • 19. Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy.
    Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Liau LM, Pope WB.
    Neuro Oncol; 2013 Mar 01; 15(3):382-90. PubMed ID: 23275575
    [Abstract] [Full Text] [Related]

  • 20. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.
    Chinot OL, de La Motte Rouge T, Moore N, Zeaiter A, Das A, Phillips H, Modrusan Z, Cloughesy T.
    Adv Ther; 2011 Apr 01; 28(4):334-40. PubMed ID: 21432029
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.